ArticleThe Journal of clinical investigation2003
A role for surface lymphotoxin in experimental autoimmune encephalomyelitis independent of LIGHT.
Article in The Journal of clinical investigation, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 64 citations in OpenAlex.
- Serum autoantibodies against α7-nicotinic receptors in subgroups of patients with bipolar disorder or schizophrenia: clinical features and link with peripheral inflammation.Translational psychiatry · 2024Article
- Lymphotoxin-alpha expression in the meninges causes lymphoid tissue formation and neurodegeneration.Brain : a journal of neurology · 2022Article
- Review
- Lymphotoxin β receptor-mediated NFκB signaling promotes glial lineage differentiation and inhibits neuronal lineage differentiation in mouse brain neural stem/progenitor cells.Journal of neuroinflammation · 2018Article
- Lymphotoxin signalling in tertiary lymphoid structures and immunotherapy.Cellular & molecular immunology · 2017Review
- Innate lymphotoxin receptor mediated signaling promotes HSV-1 associated neuroinflammation and viral replication.Scientific reports · 2015Article
- Role of Tumor Necrosis Factor Superfamily in Neuroinflammation and Autoimmunity.Frontiers in immunology · 2015Review
- The Lymphotoxin Network: orchestrating a type I interferon response to optimize adaptive immunity.Cytokine & growth factor reviews · 2014Review
- Lymphotoxin-sensitive microenvironments in homeostasis and inflammation.Frontiers in immunology · 2012Article
- Herpesvirus entry mediator (TNFRSF14) regulates the persistence of T helper memory cell populations.The Journal of experimental medicine · 2011Article
- Review
- Targeted depletion of lymphotoxin-alpha-expressing TH1 and TH17 cells inhibits autoimmune disease.Nature medicine · 2009Article
- Induction of lymphotoxin-alpha by interleukin-12 p40 homodimer, the so-called biologically inactive molecule, but not IL-12 p70.Immunology · 2009Article
- Blockade of lymphotoxin-beta receptor signaling reduces aspects of Sjögren's syndrome in salivary glands of non-obese diabetic mice.Arthritis research & therapy · 2009Article
- Targeting lymphocyte activation through the lymphotoxin and LIGHT pathways.Immunological reviews · 2008Review
- Ectopic lymphoid tissues and local immunity.Seminars in immunology · 2008Review
- Lymphotoxin beta receptor (Lt betaR): dual roles in demyelination and remyelination and successful therapeutic intervention using Lt betaR-Ig protein.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2007Article
- Expression of lymphotoxin-alphabeta on antigen-specific T cells is required for DC function.The Journal of experimental medicine · 2007Article
- Transgenic LacZ under control of Hec-6st regulatory sequences recapitulates endogenous gene expression on high endothelial venules.Proceedings of the National Academy of Sciences of the United States of America · 2007Article
- LIGHT-related molecular network in the regulation of innate and adaptive immunity.Immunologic research · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In studies using genetically deficient mice, a role for the lymphotoxin (LT) system in the pathogenesis of experimental autoimmune encephalomyelitis (EAE) has remained controversial. Here, we have reassessed this conclusion by using a fusion protein decoy that blocks the LT pathway in vivo without evoking the developmental defects inherent in LT-deficient mice. We have found that inhibition of the LT pathway prevented disease in two models of EAE that do not rely on the administration of pertussis toxin. Surprisingly, disease attenuation was due to specific blockade of LTalphabeta binding rather than the binding of LIGHT to its receptors. In a third system that requires pertussis toxin, LT inhibition did not affect disease, as was observed when the same model was used with LT-deficient mice. Disease prevention in pertussis toxin-free models was associated with defects in T cell responses and migration. When the DO11.10 T cell transgenic system was used, inhibition of the LT pathway was shown to uncouple T cell priming from T cell recall responses. Therefore, it is hypothesized that the LT pathway and its ability to maintain lymphoid microenvironments is critical for sustaining late-phase T cell responses in multiple sclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.